Cargando…
Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans
OBJECTIVE: Maladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The α(v)β(3) integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether α(v)β(3) integrin expression determines myocardial recovery follo...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566089/ https://www.ncbi.nlm.nih.gov/pubmed/27927700 http://dx.doi.org/10.1136/heartjnl-2016-310115 |
_version_ | 1783258484051017728 |
---|---|
author | Jenkins, William S A Vesey, Alex T Stirrat, Colin Connell, Martin Lucatelli, Christophe Neale, Anoushka Moles, Catriona Vickers, Anna Fletcher, Alison Pawade, Tania Wilson, Ian Rudd, James H F van Beek, Edwin J R Mirsadraee, Saeed Dweck, Marc R Newby, David E |
author_facet | Jenkins, William S A Vesey, Alex T Stirrat, Colin Connell, Martin Lucatelli, Christophe Neale, Anoushka Moles, Catriona Vickers, Anna Fletcher, Alison Pawade, Tania Wilson, Ian Rudd, James H F van Beek, Edwin J R Mirsadraee, Saeed Dweck, Marc R Newby, David E |
author_sort | Jenkins, William S A |
collection | PubMed |
description | OBJECTIVE: Maladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The α(v)β(3) integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether α(v)β(3) integrin expression determines myocardial recovery following MI. METHODS: (18)F-Fluciclatide (a novel α(v)β(3)-selective radiotracer) positron emission tomography (PET) and CT imaging and gadolinium-enhanced MRI (CMR) were performed in 21 patients 2 weeks after ST-segment elevation MI (anterior, n=16; lateral, n=4; inferior, n=1). CMR was repeated 9 months after MI. 7 stable patients with chronic total occlusion (CTO) of a major coronary vessel and nine healthy volunteers underwent a single PET/CT and CMR. RESULTS: (18)F-Fluciclatide uptake was increased at sites of acute infarction compared with remote myocardium (tissue-to-background ratio (TBR(mean)) 1.34±0.22 vs 0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBR(mean) 1.34±0.22 vs 0.70±0.03; p<0.001). There was no (18)F-fluciclatide uptake at sites of established prior infarction in patients with CTO, with activity similar to the myocardium of healthy volunteers (TBR(mean) 0.71±0.06 vs 0.70±0.03, p=0.83). (18)F-Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall motion index≥1 vs 0; TBR(mean) 0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and subendocardial infarction. Importantly, although there was no correlation with infarct size (r=0.03, p=0.90) or inflammation (C reactive protein, r=−0.20, p=0.38), (18)F-fluciclatide uptake was increased in segments displaying functional recovery (TBR(mean) 0.95±0.33 vs 0.81±0.27, p=0.002) and associated with increase in probability of regional recovery. CONCLUSION: (18)F-Fluciclatide uptake is increased at sites of recent MI acting as a biomarker of cardiac repair and predicting regions of recovery. TRIAL REGISTRATION NUMBER: NCT01813045; Post-results. |
format | Online Article Text |
id | pubmed-5566089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55660892017-08-28 Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans Jenkins, William S A Vesey, Alex T Stirrat, Colin Connell, Martin Lucatelli, Christophe Neale, Anoushka Moles, Catriona Vickers, Anna Fletcher, Alison Pawade, Tania Wilson, Ian Rudd, James H F van Beek, Edwin J R Mirsadraee, Saeed Dweck, Marc R Newby, David E Heart Coronary Artery Disease OBJECTIVE: Maladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The α(v)β(3) integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether α(v)β(3) integrin expression determines myocardial recovery following MI. METHODS: (18)F-Fluciclatide (a novel α(v)β(3)-selective radiotracer) positron emission tomography (PET) and CT imaging and gadolinium-enhanced MRI (CMR) were performed in 21 patients 2 weeks after ST-segment elevation MI (anterior, n=16; lateral, n=4; inferior, n=1). CMR was repeated 9 months after MI. 7 stable patients with chronic total occlusion (CTO) of a major coronary vessel and nine healthy volunteers underwent a single PET/CT and CMR. RESULTS: (18)F-Fluciclatide uptake was increased at sites of acute infarction compared with remote myocardium (tissue-to-background ratio (TBR(mean)) 1.34±0.22 vs 0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBR(mean) 1.34±0.22 vs 0.70±0.03; p<0.001). There was no (18)F-fluciclatide uptake at sites of established prior infarction in patients with CTO, with activity similar to the myocardium of healthy volunteers (TBR(mean) 0.71±0.06 vs 0.70±0.03, p=0.83). (18)F-Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall motion index≥1 vs 0; TBR(mean) 0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and subendocardial infarction. Importantly, although there was no correlation with infarct size (r=0.03, p=0.90) or inflammation (C reactive protein, r=−0.20, p=0.38), (18)F-fluciclatide uptake was increased in segments displaying functional recovery (TBR(mean) 0.95±0.33 vs 0.81±0.27, p=0.002) and associated with increase in probability of regional recovery. CONCLUSION: (18)F-Fluciclatide uptake is increased at sites of recent MI acting as a biomarker of cardiac repair and predicting regions of recovery. TRIAL REGISTRATION NUMBER: NCT01813045; Post-results. BMJ Publishing Group 2017-04 2016-12-07 /pmc/articles/PMC5566089/ /pubmed/27927700 http://dx.doi.org/10.1136/heartjnl-2016-310115 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Coronary Artery Disease Jenkins, William S A Vesey, Alex T Stirrat, Colin Connell, Martin Lucatelli, Christophe Neale, Anoushka Moles, Catriona Vickers, Anna Fletcher, Alison Pawade, Tania Wilson, Ian Rudd, James H F van Beek, Edwin J R Mirsadraee, Saeed Dweck, Marc R Newby, David E Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans |
title | Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans |
title_full | Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans |
title_fullStr | Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans |
title_full_unstemmed | Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans |
title_short | Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans |
title_sort | cardiac α(v)β(3) integrin expression following acute myocardial infarction in humans |
topic | Coronary Artery Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566089/ https://www.ncbi.nlm.nih.gov/pubmed/27927700 http://dx.doi.org/10.1136/heartjnl-2016-310115 |
work_keys_str_mv | AT jenkinswilliamsa cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT veseyalext cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT stirratcolin cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT connellmartin cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT lucatellichristophe cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT nealeanoushka cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT molescatriona cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT vickersanna cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT fletcheralison cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT pawadetania cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT wilsonian cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT ruddjameshf cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT vanbeekedwinjr cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT mirsadraeesaeed cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT dweckmarcr cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans AT newbydavide cardiacavb3integrinexpressionfollowingacutemyocardialinfarctioninhumans |